Cyclooxygenase-2: A Potential Target in Breast Cancer

Dingzhi Wang, Raymond N. DuBois

Research output: Contribution to journalArticle

127 Scopus citations

Abstract

Use of nonsteroidal anti-inflammatory drugs has been shown to result in a 40% to 50% reduction in the relative risk of developing colorectal cancer. Cyclooxygenase-2 (COX-2) overexpression occurs in 43% of human invasive breast cancers and 63% of ductal carcinomas in situ. There is considerable in vitro, animal model, and epidemiologic evidence to suggest that COX-2 may play some role in breast tumor initiation and progression. PGE2 is a major downstream mediator of COX-2 that promotes cellular proliferation and angiogenesis, makes cells resistant to apoptosis, enhances invasiveness, and modulates immunosuppression. COX-2 and COX-2-derived PGE2 may be involved in mammary carcinogenesis. Therefore, COX-2 selective inhibitors may have a role in breast cancer prevention.

Original languageEnglish (US)
Pages (from-to)64-73
Number of pages10
JournalSeminars in Oncology
Volume31
Issue number1 SUPPL. 3
DOIs
StatePublished - Feb 2004

    Fingerprint

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this